Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Intas Pharma

Actelion HQ Switzerland

Resurgent Actelion catches J&J’s eye

Confirms talks of possible take over after Uptravi sees ‘outstanding’ sales

- PMLiVE

Novartis buys blood disease specialist Selexys

$665m deal prompted by positive phase II data for sickle cell disease therapy

- PMLiVE

Hey You! campaign targets over 60s at high risk of stroke

Bayer launches atrial fibrillation awareness drive starring rock and roll

- PMLiVE

Pfizer to shut down two UK manufacturing sites

Over 370 jobs at the north London and Hampshire plants are at risk

EU flag

Pfizer’s first-in-class breast cancer therapy wins EU licence

Ibrance given the green light as a first-line treatment in Europe

Artificial intelligence firm licenses Janssen candidates for development

UK-based BenevolentAI aims to move them into late-stage trials by mid-2017

National Institute for Health and Care Excellence NICE logo

NICE backs Novartis’ Afinitor and Pfizer’s Xalkori

Provisionally approves breast and lung cancer drugs after greater discounts offered

- PMLiVE

NICE set to knock-back Amgen’s myeloma treatment Kyprolis

Cites uncertainty in clinical and cost-effectiveness analyses

Bristol Myers Squibb logo

BMS wins early UK access for Opdivo in Hodgkin’s lymphoma

Cancer treatment approved by the MHRA for use before EU licence in place

- PMLiVE

Torrid times at Gilead lead to calls for a major M&A deal

HIV portfolio sales down almost 10% to $7.5bn despite strong $533m start for Epclusa

- PMLiVE

‘Hard’ Brexit could mean a longer wait for new drugs, says report

Warns of deprioritised status if negotiators fail to secure access to the single market

- PMLiVE

Teva expands eHealth alliance with IBM

Taps Watson Health Cloud for drug development and disease management work

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links